SCHEMBL1017667

SCHEMBL1017667

NC(=O)C1C=CC=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19377759 0.98
Hydrochloric Acid SCHEMBL1017781 0.98
SCHEMBL819489 0.78
SCHEMBL27712435 0.76
Hydrochloric Acid SCHEMBL14741222 0.76 EGLN1 (0.37)
SCHEMBL6281766 0.76
SCHEMBL9234298 0.74
SCHEMBL23281859 0.67
SCHEMBL16963308 0.67 EGLN1 (0.47)
SCHEMBL28181190 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134514-A1 NOVEL COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2024-06-27 WO claimed
CN-117603219-A P-glycoprotein inhibitor and preparation method and application thereof 浙江大学 2024-02-27 CN claimed
EP-3600312-A1 PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 Takeda Pharmaceutical Company Limited (JP) 2020-02-05 EP claimed
WO-2018183145-A1 PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-04 WO claimed
CN-104302287-B Indolin-2-one derivatives as protein kinase inhibitors 安基生技新药股份有限公司 2017-12-26 CN claimed
EP-2900671-A1 SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES Bayer Pharma Aktiengesellschaft (DE) 2015-08-05 EP claimed
EP-2900670-A1 SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS Bayer Pharma Aktiengesellschaft (DE) 2015-08-05 EP claimed
EP-2349328-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2011-08-03 EP claimed
EP-2271624-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-01-12 EP claimed
WO-2010039248-A1 METHODS FOR THE TREATMENT OF CANCER LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 2010-04-08 WO claimed
WO-2009136663-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 WO claimed
WO-2009131245-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 WO claimed
EP-1250332-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION Abbott Laboratories (US) 2002-10-23 EP claimed
WO-2001044223-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION ABBOTT LABORATORIES (US) 2001-06-21 WO claimed
EP-0493782-A2 Novel dihydropyridine amides, process for their preparation and drugs containing them BAYER AG (DE) 1992-07-08 EP claimed
EP-0288758-B1 DIHYDROPYRIDINAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES BAYER AG (DE) 1991-08-14 EP claimed
EP-0362632-A2 Basic 4-aryl-DHP amides, process for their preparation and their pharmaceutical use BAYER AG (DE) 1990-04-11 EP claimed
EP-0288758-A2 Dihydropyridinamides, process for their preparation and their use in medicines BAYER AG (DE) 1988-11-02 EP claimed
US-20260083865-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2026-03-26 US disclosed
US-4110424-A PROCESS FOR THE PRODUCTION OF CYANIC ACID AND CARBOXAMIDES POLAROID CORPORATION (US) 1978-08-29 US disclosed